Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#111 / 200 Total
LXEH - Lixiang Education Holding Co Ltd ADR - Stock Price Chart
TickerLXEH [NASD]
CompanyLixiang Education Holding Co Ltd ADR
CountryChina
IndustryEducation & Training Services
Market Cap4.41MEPS (ttm)-12.47
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S0.79EPS next 5Y-
P/B0.19EPS Q/Q41.94%
Dividend-Sales Q/Q-43.40%
Insider Own-Inst Own1.94%
Insider Trans-Inst Trans-55.46%
Short Float-Earnings-
Analyst Recom-Target Price-
Avg Volume34.53K52W Range2.11 - 65.06
Lixiang Education Holding Co., Ltd. is an investment holding company, which engages in the provision of education services. It offers kindergarten, private primary, and secondary levels. The company was founded by Fen Ye in August 2001 and is headquartered in Lishui, China.
SGMT - Sagimet Biosciences Inc - Stock Price Chart
TickerSGMT [NASD]
CompanySagimet Biosciences Inc
CountryUSA
IndustryBiotechnology
Market Cap109.48MEPS (ttm)-1.14
P/E-EPS this Y43.11%
Forward P/E-EPS next Y-134.80%
PEG-EPS past 5Y-16.23%
P/S54.74EPS next 5Y-
P/B0.59EPS Q/Q19.85%
Dividend-Sales Q/Q-
Insider Own34.36%Inst Own53.34%
Insider Trans-0.51%Inst Trans-
Short Float9.77%EarningsAug 14/b
Analyst Recom1.33Target Price32.60
Avg Volume1.08M52W Range2.13 - 20.71
Oct-01-24 07:00AM Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH (GlobeNewswire) +12.64%
12:05AM Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-12-24 07:30AM Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit (GlobeNewswire) -9.57%
Sep-04-24 08:00AM Sagimet Biosciences to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-14-24 08:00AM Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire) -7.14%
Aug-01-24 08:00AM Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors (GlobeNewswire)
Jun-10-24 08:00AM Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat (GlobeNewswire)
Jun-06-24 05:00AM Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024 (GlobeNewswire)
May-16-24 08:00AM Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024 (GlobeNewswire)
May-15-24 12:53PM SGMT Stock Earnings: Sagimet Biosciences Beats EPS for Q1 2024 (InvestorPlace) +5.48%
Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kemble GeorgeExecutive ChairmanJul 23 '24Sale3.1723,62574,830118,693Jul 25 04:05 PM
Martins Eduardo BrunoChief Medical OfficerJul 19 '24Sale3.108,35725,91081,213Jul 23 04:06 PM
Rozek ElizabethGeneral Counsel and CCOJul 19 '24Sale3.1010,91433,830160,506Jul 23 04:05 PM
Kemble GeorgeExecutive ChairmanJul 19 '24Sale3.1014,06243,605142,318Jul 23 04:05 PM
Happel DavidPresident & CEOMar 26 '24Buy5.2712,10063,731639,200Mar 28 04:08 PM
ZBIO - Zenas Biopharma Inc. - Stock Price Chart
TickerZBIO [NASD]
CompanyZenas Biopharma Inc.
CountryUSA
IndustryBiotechnology
Market Cap737.31MEPS (ttm)-
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own-Inst Own10.05%
Insider Trans-Inst Trans-
Short Float0.00%Earnings-
Analyst Recom-Target Price-
Avg Volume271.41K52W Range16.17 - 20.50
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company. The firm is mainly engaged in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MOULDER LEON O JRChief Executive OfficerSep 18 '24Buy17.9110,000179,1001,662,039Sep 20 06:34 PM
MOULDER LEON O JRChief Executive OfficerSep 20 '24Buy18.455,00092,2701,672,039Sep 20 06:34 PM
MOULDER LEON O JRChief Executive OfficerSep 19 '24Buy17.895,00089,4501,667,039Sep 20 06:34 PM
Enavate Sciences GP, LLC10% OwnerSep 16 '24Buy17.00882,35315,000,0013,761,359Sep 18 04:15 PM
Lu HongboDirectorSep 13 '24Buy17.0058,823999,99158,823Sep 17 07:52 PM
TUSK - Mammoth Energy Services Inc - Stock Price Chart
TickerTUSK [NASD, RUT]
CompanyMammoth Energy Services Inc
CountryUSA
IndustryConglomerates
Market Cap216.10MEPS (ttm)-3.64
P/E-EPS this Y-11633.33%
Forward P/E-EPS next Y94.03%
PEG-EPS past 5Y-
P/S1.02EPS next 5Y-
P/B0.74EPS Q/Q-3365.53%
Dividend-Sales Q/Q-31.69%
Insider Own4.44%Inst Own80.74%
Insider Trans0.23%Inst Trans5.36%
Short Float0.68%EarningsAug 09/b
Analyst Recom1.00Target Price4.90
Avg Volume213.06K52W Range2.50 - 4.95
Mammoth Energy Services, Inc. engages in the exploration and development of North American onshore unconventional oil and natural gas reserves. It operates through the following segments: Infrastructure, Pressure Pumping, Natural Sand Proppant, Drilling, and Other. The Infrastructure segment offers construction, upgrade, maintenance and, repair services to the electrical infrastructure industry. The Pressure Pumping segment provides pressure pumping services, also known as hydraulic fracturing, to exploration and production companies. The Natural Sand Proppant segment refers to mining, processing, and selling sand. The Drilling segment includes contract land, directional drilling, and rig moving services. The company was founded on June 3, 2016 and is headquartered in Oklahoma City, OK.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Amron Arthur HDirectorMay 30 '24Buy3.653,00010,94418,279May 30 04:25 PM
Amron Arthur HDirectorMay 28 '24Buy3.572,0007,14815,279May 30 04:25 PM
Amron Arthur HDirectorMar 12 '24Buy3.723,00011,15713,279Mar 14 04:11 PM
Straehla ArtyChief Executive OfficerDec 19 '23Sale4.3540,000174,1601,012,107Dec 19 06:37 PM
Straehla ArtyChief Executive OfficerDec 18 '23Sale4.3830,000131,2801,052,107Dec 19 06:37 PM
APM - Aptorum Group Ltd - Stock Price Chart
TickerAPM [NASD]
CompanyAptorum Group Ltd
CountryUnited Kingdom
IndustryBiotechnology
Market Cap9.40MEPS (ttm)-0.91
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y34.83%
P/S21.86EPS next 5Y-
P/B0.38EPS Q/Q123.18%
Dividend-Sales Q/Q-100.00%
Insider Own58.20%Inst Own1.46%
Insider Trans0.00%Inst Trans346.64%
Short Float0.19%Earnings-
Analyst Recom1.00Target Price80.00
Avg Volume15.28K52W Range1.35 - 17.49
Aptorum Group Ltd. is a pharmaceutical company, which engages in the discovery, development, and commercializing of therapeutic assets to treat diseases with unmet medical needs. It operates through the Therapeutics and Non-Therapeutics segments. The Therapeutics segment seeks to develop drug molecules and certain technologies for the treatment and diagnosis of human disease conditions. The Non-Therapeutics segment encompasses diagnostics projects including a novel molecular-based rapid pathogen identification and detection diagnostics, AML Clinic, and sale of natural supplements. Its pipeline include Smart-Act, Acticule, RPIDD, Nativus, and Claves series. The company was founded by Ian Huen on September 13, 2010 and is headquartered in London, the United Kingdom.
JMIA - Jumia Technologies Ag ADR - Stock Price Chart
TickerJMIA [NYSE]
CompanyJumia Technologies Ag ADR
CountryGermany
IndustryInternet Retail
Market Cap573.51MEPS (ttm)-1.02
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y16.58%
P/S3.02EPS next 5Y-
P/B22.45EPS Q/Q31.79%
Dividend-Sales Q/Q-24.82%
Insider Own0.35%Inst Own21.92%
Insider Trans0.00%Inst Trans9.31%
Short Float7.02%EarningsAug 06/b
Analyst Recom1.00Target Price11.00
Avg Volume5.74M52W Range2.23 - 15.04
Jumia Technologies AG engages in the provision of logistic services. It operates a pan-African e-commerce platform. It operates through the following geographical segments: West Africa, North Africa, East and South Africa, Europe, United Arab Emirates, and Others. The company was founded by Jeremy Hodara, Sacha Poignonnec, Peter Allerstorfer, Manuel Koser, Tunde Kehinde, and Raphael Afaedor in 2012 and is headquartered in Berlin, Germany.
EBS - Emergent Biosolutions Inc - Stock Price Chart
TickerEBS [NYSE]
CompanyEmergent Biosolutions Inc
CountryUSA
IndustryDrug Manufacturers - Specialty & Generic
Market Cap496.44MEPS (ttm)-11.25
P/E-EPS this Y71.54%
Forward P/E6.09EPS next Y185.15%
PEG-EPS past 5Y-
P/S0.45EPS next 5Y-
P/B1.26EPS Q/Q-4.43%
Dividend-Sales Q/Q-24.62%
Insider Own3.97%Inst Own56.40%
Insider Trans-0.60%Inst Trans-1.84%
Short Float8.62%EarningsAug 06/a
Analyst Recom2.33Target Price12.00
Avg Volume3.11M52W Range1.42 - 15.10
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Zoon Kathryn CDirectorJun 04 '24Sale6.1110,00061,10054,482Jun 06 04:16 PM
Zoon Kathryn CDirectorMay 29 '24Sale4.611,8308,43664,482May 31 03:02 PM
Zoon Kathryn CDirectorMay 21 '24Sale5.781,0896,29448,882May 23 05:15 PM
BLDE - Blade Air Mobility Inc - Stock Price Chart
TickerBLDE [NASD, RUT]
CompanyBlade Air Mobility Inc
CountryUSA
IndustryAirports & Air Services
Market Cap257.17MEPS (ttm)-0.65
P/E-EPS this Y64.66%
Forward P/E-EPS next Y54.10%
PEG-EPS past 5Y-
P/S1.08EPS next 5Y-
P/B1.12EPS Q/Q12.68%
Dividend-Sales Q/Q11.41%
Insider Own36.24%Inst Own50.60%
Insider Trans-0.30%Inst Trans-1.00%
Short Float7.84%EarningsAug 07/a
Analyst Recom1.00Target Price7.38
Avg Volume579.85K52W Range2.06 - 4.24
Blade Air Mobility, Inc. engages in providing air transportation alternatives through a technology-powered and global air mobility platform. It operates through the Passenger and Medical segments. The Passenger segment includes short distance helicopter and amphibious seaplane flights and non-medical jet charter. The Medical segment is involved in the transportation of human organs for transplant. The company was founded by Robert S. Wiesenthal and Steven Martocci on December 22, 2014 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cohen AmirChief Accounting OfficerSep 11 '24Sale2.854,89113,93974,591Sep 13 12:05 PM
Wunsch Scott MCEO, Trinity Air MedicalSep 11 '24Sale2.857,74122,062284,962Sep 13 12:04 PM
Heyburn William A.Chief Financial OfficerAug 14 '24Option Exercise0.1825,0004,5001,410,586Aug 15 12:11 PM
Heyburn William A.Chief Financial OfficerJun 10 '24Option Exercise0.1830,0005,4001,443,580Jun 12 05:42 PM
Love ReginaldDirectorJun 10 '24Buy2.985,09115,19762,628Jun 12 05:42 PM
XBIO - Xenetic Biosciences Inc - Stock Price Chart
TickerXBIO [NASD]
CompanyXenetic Biosciences Inc
CountryUSA
IndustryBiotechnology
Market Cap7.05MEPS (ttm)-3.05
P/E-EPS this Y-46.38%
Forward P/E-EPS next Y34.65%
PEG-EPS past 5Y51.08%
P/S2.80EPS next 5Y-
P/B0.95EPS Q/Q-19.95%
Dividend-Sales Q/Q11.58%
Insider Own18.67%Inst Own0.97%
Insider Trans0.00%Inst Trans-29.85%
Short Float0.48%EarningsAug 13/a
Analyst Recom3.00Target Price40.00
Avg Volume16.57K52W Range2.78 - 5.20
Xenetic Biosciences, Inc. is a biopharmaceutical company engaged in the advancement of cell-based therapeutics to target the B-cell receptor on the surface of an individual patient's malignant tumor cells. Its product pipeline includes XCart Platform and Polyxen. The company was founded on August 9, 2011 and is headquartered in Framingham, MA.
JAGX - Jaguar Health Inc - Stock Price Chart
TickerJAGX [NASD]
CompanyJaguar Health Inc
CountryUSA
IndustryBiotechnology
Market Cap12.29MEPS (ttm)-37.55
P/E-EPS this Y99.27%
Forward P/E-EPS next Y-234.62%
PEG-EPS past 5Y86.10%
P/S1.21EPS next 5Y40.00%
P/B0.62EPS Q/Q90.23%
Dividend-Sales Q/Q1.68%
Insider Own16.25%Inst Own1.11%
Insider Trans0.00%Inst Trans-46.80%
Short Float4.79%EarningsAug 13/b
Analyst Recom1.00Target Price14.50
Avg Volume747.34K52W Range0.95 - 31.74
Oct-02-24 06:52AM Jaguars diarrhoea drug shows benefit in Phase III breast cancer subgroup (Clinical Trials Arena) +8.13%
Oct-01-24 08:30AM Jaguar Health Reports Statistically Significant Improvement in Breast Cancer Patients in its Phase 3 OnTarget Trial for its Cancer Supportive Care Drug Crofelemer (ACCESSWIRE) -8.89%
Sep-26-24 10:00AM Jaguar Health Scientific Advisory Board Member to Share Poster Presentation at American Society of Clinical Oncology (ASCO) Quality Care Symposium About the Methodologies Involved in Designing an Advocate-Led Quality of Life Survey for Cancer Patients and Survivors (ACCESSWIRE) +5.91%
Sep-25-24 08:30AM Jaguar Health to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024 (ACCESSWIRE)
Sep-24-24 10:00AM Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care at American Society for Radiation Oncology (ASTRO) Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024 Gelclair Launch (ACCESSWIRE)
Sep-16-24 10:00AM Jaguar Health to Present September 19 at the MedInvest Biotech & Pharma Investor Conference (ACCESSWIRE)
Sep-10-24 10:00AM Jaguar Health Appoints Industry Veteran to Head Sales for Company's Commercialized Oncology and HIV Products Including October 2024 Launch of Gelclair for Cancer Supportive Care (ACCESSWIRE)
Sep-06-24 10:00AM Jaguar Health to Present at the September 9-11 H.C. Wainwright Annual Global Investment Conference (ACCESSWIRE)
Sep-05-24 08:30AM Jaguar Health Celebrates National Service Dog Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs (ACCESSWIRE)
Sep-04-24 10:00AM New Innovators with Jane King Interview with Jaguar Health CEO Lisa Conte Spotlights Company's Near-Term Commercial & Development Milestones (ACCESSWIRE)
Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. It operates through the Human Health and Animal Health segments. The Human Health segment is involved in manufacturing human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment includes commercializing prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.
1789101112131415161720